Considering its significant role in prostate cancer progression, silencing SIRT6 in prostate cancer sites may be pharmacologically interesting, especially for the potential application in metastatic prostate cancer therapeutic strategies. The gene discussed is SIRT6; the disease is metastatic prostate carcinoma.